NCT03655002 — City of Hope Medical Center cancer immunotherapy trial
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
Registry record
| Registry ID | NCT03655002 ↗ |
|---|---|
| Lead sponsor | City of Hope Medical Center |
| Collaborators | National Cancer Institute (NCI) |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8 |
| Enrollment | 8 participants (target) |
| Start date | 2019-05-17 |
| Primary completion | 2027-03-02 (est.) |
| Last registry update | 21 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03655002), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03655002?
NCT03655002 (IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by City of Hope Medical Center.
Is NCT03655002 recruiting?
As of the 2026-08-21 registry update, NCT03655002 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03655002?
The lead sponsor is City of Hope Medical Center. Collaborators: National Cancer Institute (NCI).
What condition does NCT03655002 study?
The registered conditions are Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8. Primary completion is listed as 2027-03-02 (estimated).
Are results available for NCT03655002?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03655002.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.